Ccr5 - C-C motif chemokine receptor 5 Gene

Rattus norvegicus

Also known as Ckr5; Cmkbr5

Gene ID: 117029 | Gene type: protein coding

About Ccr5

Primary_assembly 8: 123,752,325-123,759,260 forward strand.mRatBN7.2:CM026981.1

This gene has 1 transcript (splice variant), 151 orthologues, 24 paralogues and is associated with 98 phenotypes. Biased expression in Spleen (RPKM 251.4), Thymus (RPKM 8.4) and 8 other tissues.

Summary

Enables protein kinase binding activity. Involved in several processes, including nervous system development; positive regulation of cytokine production; and response to bacterium. Located in cell surface and endosome. Used to study Alzheimer's disease; plague; and visual epilepsy. Biomarker of several diseases, including artery disease (multiple); diabetes mellitus (multiple); end stage renal disease; orchitis; and uveitis (multiple). Human ortholog(s) of this gene implicated in several diseases, including Kawasaki disease; West Nile fever; autoimmune disease (multiple); berylliosis; and sarcoidosis (multiple). Orthologous to human CCR5 (C-C motif Chemokine Receptor 5). [provided by Alliance of Genome Resources, Apr 2022]

Ccr5 Products(1)

mRNA	Protein	Name
NM_053960.3	NP_446412.2	C-C chemokine receptor type 5

Ccr5 Protein Structure

7tmA_CCR5_CCR2

0
100
200
300
354 a.a.

Protein Preferred Names

Protein Names

C-C chemokine receptor type 5

C-C CKR-5	CC-CKR-5
CCR-5	MIP-1 alpha receptor
chemokine (C-C motif) receptor 5	chemokine (C-C) receptor 5

Related Agents

Approval

Bioactive Molecules (3)

Cat. No.	Product Name	Effect	Purity	Rare Diseases
HY-13004	Maraviroc	Antagonist	99.71%	Yes
HY-117621	PF-04634817	Antagonist	98.87%	Unkown
HY-117621A	PF-04634817 succinate	Antagonist	≥99.0%	Unkown

Clinical Phase

Bioactive Molecules (7)

Cat. No.	Product Name	Effect	Purity	Phase
HY-14882	Cenicriviroc	Antagonist	99.01%	Phase 3
HY-14882A	Cenicriviroc Mesylate	Antagonist	99.04%	Phase 3
HY-17377	Vicriviroc maleate	Antagonist	99.91%	Phase 3
HY-17450A	Aplaviroc hydrochloride	Antagonist	99.76%	Phase 3
HY-17450	Aplaviroc	Antagonist	/	Phase 3
HY-109593	BMS-813160	Antagonist	99.93%	Phase 2
HY-P1034	DAPTA	Inhibitor	99.85%	Phase 2

Pre-clinical Phase

Bioactive Molecules (9)

Cat. No.	Product Name	Effect	Purity	Rare Diseases
HY-13406	TAK-779	Antagonist	99.73%	Unkown
HY-19974	TAK-220	Antagonist	99.95%	Unkown
HY-101713	Ilacirnon	Inhibitor	99.87%	Unkown
HY-119101	AZD-5672	Antagonist	≥95.0%	Yes
HY-111069	Nifeviroc	Inhibitor	98.17%	Unkown
HY-152131	CCR5 antagonist 2	Antagonist	/	Unkown
HY-111321	Fuscin	Inhibitor	/	Unkown
HY-152132	CCR5 antagonist 3	Inhibitor	/	Unkown
HY-100261	CCR5 antagonist 1	Antagonist	/	Unkown

Orthologs Information

Species	Symbol	Source	ID
Homo sapiens	Ccr5	NCBI	NCBI:1234
Mus musculus	Ccr5	NCBI	NCBI:12774

Name
Email *

	Sorry, but the email address you supplied was invalid.